<DOC>
	<DOCNO>NCT00073827</DOCNO>
	<brief_summary>The primary purpose study investigate efficacy levalbuterol compare placebo compare albuterol treatment prevention bronchoconstriction adolescent adult subject asthma , treatment administer 4 time day ( QID ) .</brief_summary>
	<brief_title>Study Levalbuterol , Racemic Albuterol Placebo Subjects Twelve Years Age Older With Asthma</brief_title>
	<detailed_description>This Phase III , multicenter , randomize , double-blind , placebo- active-controlled , parallel-group study 9 week duration . Seven day QID single-blind placebo administration ( via MDI ) follow 56 day QID double-blind active treatment . Following run-in period , subject randomize one follow three treatment : levalbuterol HFA MDI 90 mcg ( 2 actuation 45 mcg ) , racemic albuterol HFA MDI 180 mcg ( 2 actuation 90 mcg ) , placebo ( 2 actuation ) . Subjects randomized 2:1:1 ratio levalbuterol racemic albuterol placebo . In order maintain blinding device , placebo dose administer treatment . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Inclusion Criteria Willing able comply study procedure visit schedule Male female , least 12 year age Female subject 1260 year age must negative serum pregnancy test study start . Women child bear potential must use acceptable method birth control Have document diagnosis asthma minimum 6 month prior study start Must stable baseline asthma use Badrenergic agonist , and/or antiasthma antiinflammatory medication , and/or OTC asthma medication least 6 month prior study start Must good health exception reversible airway disease suffer chronic condition might affect respiratory function Must chest Xray diagnostic pneumonia , atelectasis , pulmonary fibrotic disease , pneumothorax , chronic obstructive pulmonary disease , etc . Must able complete diary card medical event calendar reliably daily basis , understand dose instruction , demonstrate use MiniWright PEF meter . Exclusion Criteria Female subject pregnant lactating Have participate investigational drug study within 30 day prior study start , currently participate another clinical trial Subject whose schedule prevents take first daily dose study medication and/or start study visit 9 AM Subject travel commitment study would interfere trial measurement compliance Have history hospitalization asthma within 45 day prior study start , schedule inpatient hospitalization , include elective surgery Have know sensitivity levalbuterol racemic albuterol , excipients formulation Subject use prescription drug albuterol sulfate administration contraindicate Subject currently diagnose lifethreatening asthma History cancer ( exception : basal cell carcinoma remission ) . Subject hyperthyroidism , diabetes , hypertension , cardiac disease seizure disorder currently well control medication History substance abuse drug abuse within 12 month precede study start Subject great 10 pack year history cigarette smoking use tobacco product within 6 month study start Documented history bronchopulmonary aspergillosis form allergic alveolitis Have suffer clinically significant upper low respiratory tract infection 2 week prior study start Subject staff member relative staff member</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>adolescent</keyword>
	<keyword>adult</keyword>
	<keyword>asthma</keyword>
	<keyword>levalbuterol</keyword>
	<keyword>bronchoconstriction</keyword>
</DOC>